Analysts Offer Predictions for Vaxcyte FY2025 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Vaxcyte in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn ($7.02) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.14) per share.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the firm earned ($0.91) EPS.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has an average rating of “Buy” and an average target price of $145.71.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $89.64 on Thursday. The firm has a market capitalization of $11.17 billion, a PE ratio of -19.49 and a beta of 0.98. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The business’s fifty day moving average price is $87.24 and its two-hundred day moving average price is $93.85.

Institutional Trading of Vaxcyte

Institutional investors have recently modified their holdings of the company. Riverview Trust Co bought a new stake in Vaxcyte in the third quarter worth about $27,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after purchasing an additional 93 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. bought a new stake in shares of Vaxcyte in the 3rd quarter worth approximately $92,000. Finally, Signaturefd LLC lifted its stake in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after purchasing an additional 358 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.82, for a total value of $1,602,300.00. Following the transaction, the chief executive officer now owns 435,219 shares in the company, valued at approximately $46,490,093.58. This trade represents a 3.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,982 shares of company stock valued at $8,108,425. Company insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.